Last reviewed · How we verify

MedSIR — Portfolio Competitive Intelligence Brief

MedSIR pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Auxiliary Medicinal Product - Dexamethasone Auxiliary Medicinal Product - Dexamethasone phase 3 Glucocorticoid (corticosteroid) Glucocorticoid receptor (GR) Immunology / Oncology (supportive care)

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · 1 shared drug class
  2. Fujian Shengdi Pharmaceutical Co., Ltd. · 1 shared drug class
  3. Generic (originally Schering) · 1 shared drug class
  4. Generic (originally Upjohn/Pfizer) · 1 shared drug class
  5. Hamad Medical Corporation · 1 shared drug class
  6. Hoffmann-La Roche · 1 shared drug class
  7. Hospital for Special Surgery, New York · 1 shared drug class
  8. Cancer Trials Ireland · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MedSIR:

Cite this brief

Drug Landscape (2026). MedSIR — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medsir. Accessed 2026-05-15.

Related